Determination of Tissue Distribution of an Intramuscular Plasmid Vaccine Using PCR and In Situ DNA Hybridization
- 10 November 1996
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (17), 2185-2194
- https://doi.org/10.1089/hum.1996.7.17-2185
Abstract
The increasing use of nucleic acid-based therapeutics has created a need for new methods of determining tissue distribution and levels. Radiolabel methods may not always be appropriate because nucleic acids are easily degraded. Quantitation using the polymerase chain reaction (PCR) has the advantage that only continuous stretches of DNA will be amplified. In situ hybridization allows detection of specific sequences in histological preparations. We have used quantitative PCR and in situ hybridization techniques to study the pharmacokinetics and distribution of PGagPol (a potential anti-HTV plasmid vaccine) in rabbits. Samples were obtained 4 hr, 24 hr, 7 days, and 28 days after intramuscular injection of 100 μg or 400 μg of plasmid. A simplified procedure for collecting and processing tissues for PCR that minimizes the risk of contamination was developed. Using PCR, plasmid was found principally in the skin and muscle of the injection site and in blood plasma. At 4 hr after dosing with 400 μg, the plasmid was detected at the injection site with mean copy numbers of 106 (in muscle) and 4 × 104 (in skin) per microgram of tissue. Plasmid copy number declined rapidly in muscle during the first 24 hr and was undetectable at 7 and 28 days after injection. The decline was slower in the skin, and the plasmid was still detectable at 28 days. With in situ hybridization, plasmid was detected in muscle, mainly in the perimysium and to a lesser degree in the endomysium and within the muscle fibers. These data indicate that quantitative PCR and in situ hybridization are sensitive methods for examining tissue distribution of DNA used for gene therapy. Determining tissue distribution of DNA administered for gene therapy poses some unique challenges. Optimally, any detection method would provide evidence for the presence of the specific DNA sequence rather than nucleotides that result from degradation. In this study, we have used quantitative PCR and in situ hybridization to determine the tissue distribution of pGagPol, a potential anti-human immunodeficiency virus (HIV) plasmid vaccine, after direct intramuscular injection.Keywords
This publication has 21 references indexed in Scilit:
- Cancer Gene Therapy Using Plasmid DNA: Safety Evaluation in Rodents and Non-Human PrimatesHuman Gene Therapy, 1995
- Recombinant Retroviral Vector Delivered Intramuscularly Localizes to the Site of Injection in MiceHuman Gene Therapy, 1994
- DNA Inoculation Induces Neutralizing Immune Responses Against Human Immunodeficiency Virus Type 1 in Mice and Nonhuman PrimatesDNA and Cell Biology, 1993
- Improved gene transfer by direct plasmid injection associated with regeneration in mouse skeletal muscleFEBS Letters, 1993
- Direct Gene Transfer into Skeletal MuscleIn Vivo: Factors Affecting Efficiency of Transfer and Stability of ExpressionHuman Gene Therapy, 1993
- Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral ProteinScience, 1993
- Gene Transfer In Vivo with DNA–Liposome Complexes: Lack of Autoimmunity and Gonadal LocalizationHuman Gene Therapy, 1992
- Long-term persistence of plasmid DNA and foreign gone expression in mouse muscleHuman Molecular Genetics, 1992
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990
- The rabbit C family of short, interspersed repeatsJournal of Molecular Biology, 1984